Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclizine is a piperazine-derivative antihistamine and antiemetic used for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo. It is also used to manage nausea caused by general anesthesia after surgery, cancer treatments or other medicines, as well as inner ear problems such as Ménière's disease. Cyclizine acts primarily as a histamine H1 receptor antagonist in the brain but also exerts central anticholinergic (antimuscarinic) effects. Its antiemetic action may involve depression of labyrinth excitability and vestibular stimulation along with possible effects on the medullary chemoreceptor trigger zone. The drug was originally developed by Burroughs Wellcome (now part of GSK) in the United States[5][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclizine.